(Q35779289)

10 August 2017

1 reference

title

Emerging drugs for head and neck cancer (English)

1 reference

10 August 2017

main subject

head and neck carcinoma

1 reference

John C Rhee

1

1 reference

10 August 2017

Fadlo R Khuri

series ordinal

2

1 reference

10 August 2017

Dong M Shin

series ordinal

3

1 reference

10 August 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

Expert Opinion on Emerging Drugs

10 August 2017

published in

1 reference

10 August 2017

volume

9

1 reference

10 August 2017

issue

1

1 reference

10 August 2017

page(s)

91-104

1 reference

10 August 2017

cites work

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

High-dose cisplatin for locally advanced or metastatic head and neck cancer. A phase II pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Receptors for epidermal growth factor and other polypeptide mitogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Epidermal growth factor receptors in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Severe acute interstitial pneumonia and gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Tumor necrosis factor (TNF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Inhibition of proteasome function induced apoptosis in gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

13-cis-retinoic acid in the treatment of oral leukoplakia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Colon cancer: a role for cyclo-oxygenase-2-specific nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Rationale and feasibility of chemoprovention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Antiangiogenic and chemopreventive activities of celecoxib in oral carcinoma cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.9.1.91

21 January 2018

Identifiers

DOI

10.1517/14728214.9.1.91

1 reference

10 August 2017

1 reference